 Israel Institute for Biological Research IIBR has posted scientific results from an initial sample of Phase 2 vaccinated patients to assess the BriLife vaccine against the COVID-19 Delta variant. Blood Sera from an initial sample of 11 trial participants demonstrated effective neutralizing antibodies against the original wild-type virus and was tested for antibodies to the Delta variant. 